![[ICO]](/icons/blank.gif) | Name | Last modified | Size | Description |
|---|
|
|---|
![[PARENTDIR]](/icons/back.gif) | Parent Directory | | - | |
![[ ]](/icons/layout.gif) | abemaciclib-mamar.pdf | 2022-11-14 04:17 | 598K | |
| abirateron-meta-hormonosensibil-risc-crescut.pdf | 2022-11-14 04:17 | 202K | |
| abirateron-postchimio.pdf | 2022-11-14 04:17 | 640K | |
| abirateron-prechimio.pdf | 2022-11-14 04:17 | 674K | |
| aflibercept.pdf | 2022-11-14 04:17 | 176K | |
| alectinib.pdf | 2022-11-14 04:17 | 240K | |
| atezolizumab-hepatocelular.pdf | 2022-11-14 04:17 | 246K | |
| atezolizumab-nsclc-combi.pdf | 2022-11-14 04:17 | 433K | |
| atezolizumab-nsclc-mono.pdf | 2022-11-14 04:17 | 451K | |
| atezolizumab-sclc.pdf | 2022-11-14 04:17 | 427K | |
| atezolizumab-tnbc.pdf | 2022-11-14 04:17 | 447K | |
| atezolizumab-urotelial.pdf | 2022-11-14 04:17 | 436K | |
| avelumab-merkel.pdf | 2022-11-14 04:17 | 425K | |
| avelumab-renal.pdf | 2022-11-14 04:17 | 449K | |
| avelumab-urotelial.pdf | 2022-11-14 04:17 | 273K | |
| bevacizumab-col-uterin.pdf | 2022-11-14 04:17 | 217K | |
| bevacizumab-colorectal.pdf | 2022-11-14 04:17 | 248K | |
| bevacizumab-mamar.pdf | 2022-11-14 04:17 | 246K | |
| bevacizumab-nsclc-nscc.pdf | 2022-11-14 04:17 | 252K | |
| bevacizumab-ovar.pdf | 2022-11-14 04:17 | 186K | |
| bevacizumab-renal.pdf | 2022-11-14 04:17 | 114K | |
| cabazitaxel.pdf | 2022-11-14 04:17 | 102K | |
| cabozantinib-hepatocelular.pdf | 2022-11-14 04:17 | 444K | |
| cabozantinib-renal.pdf | 2022-11-14 04:17 | 241K | |
| cemiplimab-scc-piele.pdf | 2022-11-14 04:17 | 438K | |
| ceritinib.pdf | 2022-11-14 04:17 | 232K | |
| cetuximab-cap-si-gat-metastatic.pdf | 2022-11-14 04:17 | 621K | |
| cetuximab-colorectal.pdf | 2022-11-14 04:17 | 558K | |
| crizotinib.pdf | 2022-11-14 04:17 | 235K | |
| dabrafenib-trametinib.pdf | 2022-11-14 04:17 | 246K | |
| durvalumab-nsclc.pdf | 2022-11-14 04:17 | 620K | |
| durvalumab-sclc.pdf | 2022-11-14 04:17 | 447K | |
| enzalutamid-postchimio.pdf | 2022-11-14 04:17 | 269K | |
| enzalutamid-prechimio.pdf | 2022-11-14 04:17 | 277K | |
| erlotinib-pancreas.pdf | 2022-11-14 04:17 | 217K | |
| erlotinib-pulmonar.pdf | 2022-11-14 04:17 | 226K | |
| everolimus-renal.pdf | 2022-11-14 04:17 | 227K | |
| everolimus-tumori-neuroendocrine.pdf | 2022-11-14 04:17 | 229K | |
| gefitinib.pdf | 2022-11-14 04:17 | 209K | |
| imatinib-deramatofibrosarcoma-protuberans.pdf | 2022-11-14 04:17 | 169K | |
| imatinib-gist.pdf | 2022-11-14 04:17 | 180K | |
| ipilimumab-melanom.pdf | 2022-11-14 04:17 | 565K | |
| lapatinib-linia-1.pdf | 2022-11-14 04:17 | 110K | |
| lapatinib-meta.pdf | 2022-11-14 04:17 | 190K | |
| lonsurf.pdf | 2022-11-14 04:17 | 203K | |
| lorlatinib-nsclc.pdf | 2022-11-14 04:17 | 337K | |
| nivo-ipi-renal.pdf | 2022-11-14 04:17 | 621K | |
| nivolumab-cap-si-gat.pdf | 2022-11-14 04:17 | 268K | |
| nivolumab-gastric.pdf | 2022-11-14 04:17 | 230K | |
| nivolumab-melanom.pdf | 2022-11-14 04:17 | 308K | |
| nivolumab-nsclc.pdf | 2022-11-14 04:17 | 245K | |
| nivolumab-renal.pdf | 2022-11-14 04:17 | 244K | |
| olaparib-ovar-mono.pdf | 2022-11-14 04:17 | 446K | |
| olaparib-over-combi.pdf | 2022-11-14 04:17 | 428K | |
| olaparib-prostata.pdf | 2022-11-14 04:17 | 93K | |
| olaratumab-sarcom.pdf | 2022-11-14 04:17 | 481K | |
| onyvide-pancreas.pdf | 2022-11-14 04:17 | 556K | |
| osimertinib-nsclc.pdf | 2022-11-14 04:17 | 457K | |
| palbociclib-mamar.pdf | 2022-11-14 04:17 | 65K | |
| panitumumab-colorectal.pdf | 2022-11-14 04:17 | 114K | |
| pazopanib-renal.pdf | 2022-11-14 04:17 | 287K | |
| pazopanib-sarcom.pdf | 2022-11-14 04:17 | 350K | |
| pembrolizumab-melanom.pdf | 2022-11-14 04:17 | 256K | |
| pembrolizumab-nsclc-carbo-txl.pdf | 2022-11-14 04:17 | 227K | |
| pembrolizumab-nsclc-mono.pdf | 2022-11-14 04:17 | 199K | |
| pembrolizumab-nsclc-pemetrexed.pdf | 2022-11-14 04:17 | 205K | |
| pemetrexed-mezoteliom.pdf | 2022-11-14 04:17 | 177K | |
| pemetrexed-nsclc.pdf | 2022-11-14 04:17 | 126K | |
| pertuzumab-trastuzumab-mamar.pdf | 2022-11-14 04:17 | 452K | |
| ramucirumab-gastric.pdf | 2022-11-14 04:17 | 481K | |
| ramucirumab-nsclc.pdf | 2022-11-14 04:17 | 441K | |
| regorafenib-hepatocelular.pdf | 2022-11-14 04:17 | 336K | |
| ribociclib-mamar.pdf | 2022-11-14 04:17 | 232K | |
| sorafenib-hepatocelular.pdf | 2022-11-14 04:17 | 113K | |
| sorafenib-renal.pdf | 2022-11-14 04:17 | 116K | |
| sorafenib-tiroida.pdf | 2022-11-14 04:17 | 108K | |
| sunitinib-gist.pdf | 2022-11-14 04:17 | 122K | |
| sunitinib-neuroendocrine.pdf | 2022-11-14 04:17 | 589K | |
| sunitinib-renal.pdf | 2022-11-14 04:17 | 128K | |
| tivozanib-renal.pdf | 2022-11-14 04:17 | 454K | |
| trabectedin-ovar.pdf | 2022-11-14 04:17 | 222K | |
| trabectedin-sarcom.pdf | 2022-11-14 04:17 | 224K | |
| trastuzumab-emtansine.pdf | 2022-11-14 04:17 | 676K | |
| tumori-neuroendocrine.pdf | 2022-11-14 04:17 | 539K | |
| vandetanib-medular-tiroidian.pdf | 2022-11-14 04:17 | 232K | |
| vemurafenib.pdf | 2022-11-14 04:17 | 243K | |
| trastuzumab-gastric-metastatic.pdf | 2023-02-10 09:36 | 229K | |
| trastuzumab-san-metastatic.pdf | 2023-02-10 09:36 | 189K | |
|
|---|